const contents = { "guidances" : `
  <h1 class="subtitle">Guidances</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/LawsRegulationsGuidance/default.htm">Laws, Regulations & Guidance</a></li>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm">CFR – Code of Federal Regulations Title 21</a></li>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11">21 CFR Part 11 Electronic Records, Electronic Signature</a></li>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312">21 CFR Part 312 IND Application</a></li>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=211&showFR=1">21 CFR Part 211 Current GMP for Finished Pharmaceuticals</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm362663.htm">IND Safety Report and Annual Report</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/default.htm">Guidance, Compliance, & Regulatory Information</a></li>
    <li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm">Guidance, Compliance & Regulatory Information (Biologics)</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm">Guidances (Drugs)</a></li>
    <li><a target="_blank" href="http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title5-section552b&num=0&edition=prelim">Government in the Sunshine Act (5 U.S.C. 552b)</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM466495.pdf">Purchasing Control</a></li>
  </ul>
`, "regulatory": `
  <h1 class="subtitle">Regulatory Pathway</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm">Investigational New Drug (IND) Application</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/default.htm">New Drug Application (NDA)</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/default.htm">Therapeutic Biologics Applications (BLA)</a></li>
    <li><a target="_blank" href="/files/RMAT_Nov17.pdf">Expedited Programs for Regenerative Medicine Therapies for Serious Conditions</a></li>
    <li><a target="_blank" href="https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm585414.pdf">Guidance for Industry&nbsp;Expedited Programs for Serious Conditions – Drugs and Biologics</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM423325.pdf">Rare Pediatric Disease Priority Review Vouchers, Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM589710.pdf">Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases﻿</a></li>
    <li><a target="_blank" href="https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=0e737d105ef9a1632b19a1e713b93cc4&amp;mc=true&amp;n=pt21.5.316&amp;r=PART&amp;ty=HTML">21 Code Federal Regulations Part 316 - Orphan Drugs</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/UCM517741.pdf">Public Law 97-414 To amend Federal Food, Drug, and Cosmetic Act to facilitate the development of drugs for rare diseases and conditions</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm498793.pdf">Special Protocol Assessment Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/UCM359956.pdf">Strategy and Implementation Plan for Advancing Regulatory Science</a></li>
    <li><a target="_blank" href="https://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm267719.htm">Advancing Regulatory Science at FDA</a></li>
  </ul>
`, "rmat": `
  <h1 class="subtitle">RMAT</h1> 
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM081670.pdf">Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/UCM092705.pdf">Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM078694.pdf">Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM590118.pdf">Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidances/ucm070273.pdf">Guidance for Industry&nbsp;CGMP for Phase 1 Investigational Drugs</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidances/ucm495891.pdf">Data Integrity and&nbsp;Compliance With&nbsp;CGMP Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM091345.pdf">Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585403.pdf">Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue- Based Products: Minimal Manipulation and Homologous Use</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM243392.pdf">Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM078723.pdf">Guidance for Industry; Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM466625.pdf">Recommendations for Microbial Vectors Used for Gene Therapy; Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM439273.pdf">Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products; Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/.../CellularandGeneTherapy/UCM376521.pdf">Preclinical Assessment of Investigational Cellular and Gene Therapy Products</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM564952.pdf">Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM376521.pdf">Guidance for Industry: Princlinical Assessment of Investigational Cellular and Gene Therapy Products</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588857.pdf">Drug Products,&nbsp;Including Biological&nbsp;Products, that Contain&nbsp;Nanomaterials</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/Guidances/UCM070337.pdf">Quality Systems Approach to Pharmaceutical CGMP Regulations</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/Guidances/ucm073511.pdf">Q9 Quality Risk Management</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidances/ucm353925.pdf">Contract Manufacturing&nbsp;Arrangements for Drugs:&nbsp;Quality Agreements</a></li>
  </ul>
`, "gcp": `
  <h1 class="subtitle">GCP</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/ucm113709.htm">Information Sheet Guidance for Institutional Review Boards (IRBs), Clinical Investigators, and Sponsors</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588857.pdf">Guidance for Clinical Trial Sponsors</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071682.pdf">General Considerations for the Clinical Evaluation of Drugs</a></li>
    <li><a target="_blank" href="https://www.fda.gov/RegulatoryInformation/Guidances/ucm122046.htm">Clinical Trials Guidance Documents</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf">Clinical Considerations for Therapeutic Cancer Vaccine</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf">Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127073.pdf">Establishment and Operation of Clinical Trial Data Monitoring Committees</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM268555.pdf">Clinical Trial Imaging&nbsp;Endpoint Process&nbsp;Standards Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072008.pdf">Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf">Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071696.pdf">Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072069.pdf">Waiver of IRB Requirements for Drug and Biological Product Studies</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126396.pdf">Collection of Race and Ethnicity Data in Clinical Trials</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM299138.pdf">GUIDELINE FOR POSTMARKETING REPORTING OF ADVERSE DRUG EXPERIENCES</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM249673.pdf">Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors Exception from Informed Consent Requirements for Emergency Research</li></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM259421.pdf">Clinical Trial Endpoints&nbsp;for the Approval of Non-Small Cell Lung Cancer&nbsp;Drugs and Biologics</a></li>
  </ul>
`, "21cfr": `
  <h1 class="subtitle">21 CFR Part 11</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11&amp;showFR=1">CFR - Code of Federal Regulations Title 21 Part 11</a></li>
    <li><a target="_blank" href="https://www.fda.gov/RegulatoryInformation/Guidances/ucm125067.htm">Part 11, Electronic Records; Electronic Signatures — Scope and Application</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidances/ucm495891.pdf">Data Integrity and&nbsp;Compliance With&nbsp;CGMP Guidance for Industry</a></li>
  </ul>
`, "esubmissions": `
  <h1 class="subtitle">eSubmissions</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm309911.htm">Electronic Common Technical Document (eCTD) v4.0</a></li>
    <li><a target="_blank" href="https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/AboutESG/ucm334359.htm">ESG User Guide</a></li>
    <li><a target="_blank" href="https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/CreateanESGAccount/default.htm">Create an ESG Account&nbsp;</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm330116.htm" target="">Submit Using eCTD</a></li>
    <li><a target="_blank" href="https://www.fda.gov/AboutFDA/ReportsManualsForms/Forms/default.htm">FDA Forms</a></li>
    <li><a target="_blank" href="https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/AboutESG/ucm334439.htm#3_3_1">Understand Submission Guidelines</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/default.htm">Electronic Regulatory Submission and Review (CDER)</a></li>
    <li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/ucm163685.htm">Regulatory Submissions in Electronic Format for Biologic Products (CBER)<br></a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM179118.pdf">Providing Regulatory Submissions to CBER in Electronic Format - Lot Release Protocols (CBER)</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm333969.pdf">Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071665.pdf">GUIDELINE FOR THE FORMAT AND CONTENT&nbsp;</a>OF THE CLINICAL AND STATISTICAL SECTIONS OF AN APPLICATION</li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/UCM523539.pdf">Technical Rejection Criteria for Study Data</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072053.pdf">Submission of Abbreviated Reports and Synopses in Support of Marketing Applications</a></li>
    <li><a target="_blank" href="https://www.fda.gov/forindustry/userfees/prescriptiondruguserfee/default.htm">Prescription Drug User <b>Fee</b> Act (PDUFA)</a></li>
  </ul>
`, "odac": `
  <h1 class="subtitle">ODAC/Meetings</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm">Advisory Committee Calendar</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM590547.pdf">Formal Meetings&nbsp;Between the FDA and&nbsp;Sponsors or Applicants&nbsp;of PDUFA Products Guidance for Industry</a></li>
  </ul>
`, "rems": `
  <h1 class="subtitle">REMS</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf">Format and Content of a REMS Document Guidance for Industry; Draft Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM584202.pdf">Use of a Drug Master File for Shared System REMS Submissions; Draft Guidance for Industry</a></li>
    <li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM078719.pdf">Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events</a></li>
  </ul>
`, "drugs": `
  <h1 class="subtitle">Drugs@FDA</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm">Drugs@FDA: FDA Approved Drug Products Database</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm">Orange Book Preface</a></li>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm">Orange Book</a></li>
    <li><a target="_blank" href="https://www.drugpatentwatch.com/subscribe.php">Archived Orange Book Order</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm115894.htm">FAERS</a></li>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home">MedWatch</a></li>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/ora/pcb/index.cfm">Product Code Builder</a></li>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/ora/pcb/index.cfm?action=tutorial.tutorial">PCB Tutorial</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/DrugRegistrationandListing/ucm307027.htm">DUNS</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm549668.htm">DUNS Mar 2017</a></li>
  </ul>
`, "odd": `
  <h1 class="subtitle">ODD Database</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm#Search_param_field#Search_param_field">accessdata.fda.gov/…isting/oopd/index.cfm</a></li>
  </ul>
`, "otat": `
  <h1 class="subtitle">OTAT Approvals</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/default.htm">Approved Cellular and Gene Therapy Products</a></li>
  </ul>
`, "kymriah": `
  <h1 class="subtitle">KYMRIAH</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm573706.htm">KYMRIAH (tisagenlecleucel)</a> - Novartis Pharmaceuticals Corporation</li>
  </ul>
`, "yescarta": `
  <h1 class="subtitle">YESCARTA</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm">YESCARTA (axicabtagene ciloleucel) - Kite Pharma, Incorporated</a></li>
  </ul>
`, "luxturna": `
  <h1 class="subtitle">LUXTURNA</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm589507.htm">LUXTURNA</a> - Spark Therapeutics, Inc</li>
  </ul>
`, "sbia": `
  <h1 class="subtitle">SBIA</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm483822.htm">CDER SBIA Learn</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/default.htm">CDER Small Business &amp; Industry Assistance (SBIA)</a></li>
    <li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm114027.htm">Request a Pre-Assigned Application Number</a></li>
    <li><a target="_blank" href="https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/ucm432575.htm">LOA Template</a></li>
  </ul>
`, "presentations": `
  <h1 class="subtitle">Presentations</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="/files/Jakob-Reiser.pdf">CMC for CAR-T Therapy</a></li>
    <li><a target="_blank" href="/files/Kristin-Baird.pdf">FDA 101: CLINICAL REGULATORY CONSIDERATIONS AND APPROVAL PATHWAYS FOR (CAR-T) CELL &amp; GENE THERAPIES</a></li>
  </ul>
`, "anti-pd-1": `
  <h1 class="subtitle">Anti-PD-1 mAb</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab"><span style="color: #222222; font-family: Arial;" data-mce-style="color: #222222; font-family: Arial;">Nivolumab</span>, marketed as </a>Opdivo;&nbsp;a first line treatment for inoperable or <a target="_blank" class="mw-redirect" title="Metastatic melanoma" href="https://en.wikipedia.org/wiki/Metastatic_melanoma" data-mce-href="https://en.wikipedia.org/wiki/Metastatic_melanoma">metastatic melanoma</a> in combination with <a target="_blank" title="Ipilimumab" href="https://en.wikipedia.org/wiki/Ipilimumab" data-mce-href="https://en.wikipedia.org/wiki/Ipilimumab">ipilimumab</a> if the cancer does not have a mutation in <a target="_blank" title="BRAF (gene)" href="https://en.wikipedia.org/wiki/BRAF_(gene)" data-mce-href="https://en.wikipedia.org/wiki/BRAF_(gene)">BRAF</a>,<sup id="cite_ref-FDALabel_2-4" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2">[2]</a></sup> and as a second-line treatment for inoperable or metastatic melanoma following treatment of <a target="_blank" title="Ipilimumab" href="https://en.wikipedia.org/wiki/Ipilimumab" data-mce-href="https://en.wikipedia.org/wiki/Ipilimumab">ipilimumab</a> and, if the cancer has a BRAF mutation, a <a target="_blank" class="mw-redirect" title="BRAF inhibitor" href="https://en.wikipedia.org/wiki/BRAF_inhibitor" data-mce-href="https://en.wikipedia.org/wiki/BRAF_inhibitor">BRAF inhibitor</a>.<sup id="cite_ref-FDALabel_2-5" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2">[2]</a></sup><sup id="cite_ref-2015revMel_3-1" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-2015revMel-3" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-2015revMel-3">[3]</a></sup> It is also used to treat metastatic squamous <a target="_blank" class="mw-redirect" title="Non-small cell lung cancer" href="https://en.wikipedia.org/wiki/Non-small_cell_lung_cancer" data-mce-href="https://en.wikipedia.org/wiki/Non-small_cell_lung_cancer">non-small cell lung cancer</a> with progression with or after <a target="_blank" title="Platinum-based antineoplastic" href="https://en.wikipedia.org/wiki/Platinum-based_antineoplastic" data-mce-href="https://en.wikipedia.org/wiki/Platinum-based_antineoplastic">platinum-based drugs</a>.<sup id="cite_ref-FDALabel_2-6" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2">[2]</a></sup><sup id="cite_ref-2015revNSCLC_4-1" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-2015revNSCLC-4" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-2015revNSCLC-4">[4]</a></sup> It also used as a second-line treatment for <a target="_blank" title="Renal cell carcinoma" href="https://en.wikipedia.org/wiki/Renal_cell_carcinoma" data-mce-href="https://en.wikipedia.org/wiki/Renal_cell_carcinoma">renal cell carcinoma</a> after anti-angiogenic treatment has failed.<sup id="cite_ref-FDALabel_2-7" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2">[2]</a></sup><b><sup id="cite_ref-FDALabel_2-7" class="reference"></sup></b></p></li>
  </ul>
`, "egfr": `
  <h1 class="subtitle">EGFR mAb</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://en.wikipedia.org/wiki/Cetuximab">cetuximab (Erbitux):&nbsp; metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer; BMS (US &amp; Canada),&nbsp;Merck KGaA (ROW except Japan), BMS, Merck KGaA, and&nbsp;Eli Lilly (Japan); 2009.﻿</a></li>
  </ul>
`, "ctla-4": `
  <h1 class="subtitle">CTLA-4 mAb</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://en.wikipedia.org/wiki/Ipilimumab"><span style="color: #222222; font-family: Arial;" data-mce-style="color: #222222; font-family: Arial;">﻿Ipilimumab</span> (trade name Yervoy) melanoma, BMS, 2011</a></li>
  </ul>
`};

const itemList = [
  `<li><a target="_blank" href="https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/LawsRegulationsGuidance/default.htm">Laws, Regulations & Guidance</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm">CFR – Code of Federal Regulations Title 21</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11">21 CFR Part 11 Electronic Records, Electronic Signature</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312">21 CFR Part 312 IND Application</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=211&showFR=1">21 CFR Part 211 Current GMP for Finished Pharmaceuticals</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm362663.htm">IND Safety Report and Annual Report</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/default.htm">Guidance, Compliance, & Regulatory Information</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm">Guidance, Compliance & Regulatory Information (Biologics)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm">Guidances (Drugs)</a></li>`,
  `<li><a target="_blank" href="http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title5-section552b&num=0&edition=prelim">Government in the Sunshine Act (5 U.S.C. 552b)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM466495.pdf">Purchasing Control</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm">Investigational New Drug (IND) Application</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/default.htm">New Drug Application (NDA)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/default.htm">Therapeutic Biologics Applications (BLA)</a></li>`,
  `<li><a target="_blank" href="/files/RMAT_Nov17.pdf">Expedited Programs for Regenerative Medicine Therapies for Serious Conditions</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm585414.pdf">Guidance for Industry&nbsp;Expedited Programs for Serious Conditions – Drugs and Biologics</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM423325.pdf">Rare Pediatric Disease Priority Review Vouchers, Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM589710.pdf">Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases﻿</a></li>`,
  `<li><a target="_blank" href="https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=0e737d105ef9a1632b19a1e713b93cc4&amp;mc=true&amp;n=pt21.5.316&amp;r=PART&amp;ty=HTML">21 Code Federal Regulations Part 316 - Orphan Drugs</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/UCM517741.pdf">Public Law 97-414 To amend Federal Food, Drug, and Cosmetic Act to facilitate the development of drugs for rare diseases and conditions</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm498793.pdf">Special Protocol Assessment Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/UCM359956.pdf">Strategy and Implementation Plan for Advancing Regulatory Science</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm267719.htm">Advancing Regulatory Science at FDA</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM081670.pdf">Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/UCM092705.pdf">Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM078694.pdf">Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM590118.pdf">Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidances/ucm070273.pdf">Guidance for Industry&nbsp;CGMP for Phase 1 Investigational Drugs</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidances/ucm495891.pdf">Data Integrity and&nbsp;Compliance With&nbsp;CGMP Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM091345.pdf">Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585403.pdf">Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue- Based Products: Minimal Manipulation and Homologous Use</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM243392.pdf">Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM078723.pdf">Guidance for Industry; Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM466625.pdf">Recommendations for Microbial Vectors Used for Gene Therapy; Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM439273.pdf">Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products; Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/.../CellularandGeneTherapy/UCM376521.pdf">Preclinical Assessment of Investigational Cellular and Gene Therapy Products</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM564952.pdf">Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM376521.pdf">Guidance for Industry: Princlinical Assessment of Investigational Cellular and Gene Therapy Products</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588857.pdf">Drug Products,&nbsp;Including Biological&nbsp;Products, that Contain&nbsp;Nanomaterials</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/Guidances/UCM070337.pdf">Quality Systems Approach to Pharmaceutical CGMP Regulations</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/Guidances/ucm073511.pdf">Q9 Quality Risk Management</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidances/ucm353925.pdf">Contract Manufacturing&nbsp;Arrangements for Drugs:&nbsp;Quality Agreements</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/ucm113709.htm">Information Sheet Guidance for Institutional Review Boards (IRBs), Clinical Investigators, and Sponsors</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588857.pdf">Guidance for Clinical Trial Sponsors</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071682.pdf">General Considerations for the Clinical Evaluation of Drugs</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/RegulatoryInformation/Guidances/ucm122046.htm">Clinical Trials Guidance Documents</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf">Clinical Considerations for Therapeutic Cancer Vaccine</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf">Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127073.pdf">Establishment and Operation of Clinical Trial Data Monitoring Committees</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM268555.pdf">Clinical Trial Imaging&nbsp;Endpoint Process&nbsp;Standards Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072008.pdf">Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf">Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071696.pdf">Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072069.pdf">Waiver of IRB Requirements for Drug and Biological Product Studies</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126396.pdf">Collection of Race and Ethnicity Data in Clinical Trials</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM299138.pdf">GUIDELINE FOR POSTMARKETING REPORTING OF ADVERSE DRUG EXPERIENCES</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM249673.pdf">Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors Exception from Informed Consent Requirements for Emergency Research</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM259421.pdf">Clinical Trial Endpoints&nbsp;for the Approval of Non-Small Cell Lung Cancer&nbsp;Drugs and Biologics</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11&amp;showFR=1">CFR - Code of Federal Regulations Title 21 Part 11</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/RegulatoryInformation/Guidances/ucm125067.htm">Part 11, Electronic Records; Electronic Signatures — Scope and Application</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidances/ucm495891.pdf">Data Integrity and&nbsp;Compliance With&nbsp;CGMP Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm309911.htm">Electronic Common Technical Document (eCTD) v4.0</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/AboutESG/ucm334359.htm">ESG User Guide</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/CreateanESGAccount/default.htm">Create an ESG Account&nbsp;</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm330116.htm" target="">Submit Using eCTD</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/AboutFDA/ReportsManualsForms/Forms/default.htm">FDA Forms</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/AboutESG/ucm334439.htm#3_3_1">Understand Submission Guidelines</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/default.htm">Electronic Regulatory Submission and Review (CDER)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/ucm163685.htm">Regulatory Submissions in Electronic Format for Biologic Products (CBER)<br /></a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/UCM179118.pdf">Providing Regulatory Submissions to CBER in Electronic Format - Lot Release Protocols (CBER)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm333969.pdf">Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071665.pdf">GUIDELINE FOR THE FORMAT AND CONTENT&nbsp;</a>OF THE CLINICAL AND STATISTICAL SECTIONS OF AN APPLICATION</li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/UCM523539.pdf">Technical Rejection Criteria for Study Data</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072053.pdf">Submission of Abbreviated Reports and Synopses in Support of Marketing Applications</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/forindustry/userfees/prescriptiondruguserfee/default.htm">Prescription Drug User <b>Fee</b> Act (PDUFA)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm">Advisory Committee Calendar</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM590547.pdf">Formal Meetings&nbsp;Between the FDA and&nbsp;Sponsors or Applicants&nbsp;of PDUFA Products Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf">Format and Content of a REMS Document Guidance for Industry; Draft Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM584202.pdf">Use of a Drug Master File for Shared System REMS Submissions; Draft Guidance for Industry</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM078719.pdf">Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm">Drugs@FDA: FDA Approved Drug Products Database</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm">Orange Book Preface</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm">Orange Book</a></li>`,
  `<li><a target="_blank" href="https://www.drugpatentwatch.com/subscribe.php">Archived Orange Book Order</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm115894.htm">FAERS</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home">MedWatch</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/ora/pcb/index.cfm">Product Code Builder</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/ora/pcb/index.cfm?action=tutorial.tutorial">PCB Tutorial</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/DrugRegistrationandListing/ucm307027.htm">DUNS</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm549668.htm">DUNS Mar 2017</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm#Search_param_field#Search_param_field">accessdata.fda.gov/…isting/oopd/index.cfm</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/default.htm">Approved Cellular and Gene Therapy Products</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/default.htm">Approved Cellular and Gene Therapy Products</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm573706.htm">KYMRIAH (tisagenlecleucel)</a> - Novartis Pharmaceuticals Corporation</li>`,
  `<li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm">YESCARTA (axicabtagene ciloleucel) - Kite Pharma, Incorporated</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm589507.htm">LUXTURNA</a> - Spark Therapeutics, Inc</li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm483822.htm">CDER SBIA Learn</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/default.htm">CDER Small Business &amp; Industry Assistance (SBIA)</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm114027.htm">Request a Pre-Assigned Application Number</a></li>`,
  `<li><a target="_blank" href="https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/ucm432575.htm">LOA Template</a></li>`,
  `<li><a target="_blank" href="/files/Jakob-Reiser.pdf">CMC for CAR-T Therapy</a></li>`,
  `<li><a target="_blank" href="/files/Kristin-Baird.pdf">FDA 101: CLINICAL REGULATORY CONSIDERATIONS AND APPROVAL PATHWAYS FOR (CAR-T) CELL &amp; GENE THERAPIES</a></li>`,
  `<li>
    <a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab"><span style="color: #222222; font-family: Arial;" data-mce-style="color: #222222; font-family: Arial;">Nivolumab</span>, marketed as </a>Opdivo;&nbsp;a first line treatment for inoperable or <a target="_blank" class="mw-redirect" title="Metastatic melanoma" href="https://en.wikipedia.org/wiki/Metastatic_melanoma" data-mce-href="https://en.wikipedia.org/wiki/Metastatic_melanoma">metastatic melanoma</a> in combination with <a target="_blank" title="Ipilimumab" href="https://en.wikipedia.org/wiki/Ipilimumab" data-mce-href="https://en.wikipedia.org/wiki/Ipilimumab">ipilimumab</a> if the cancer does not have a mutation in <a target="_blank" title="BRAF (gene)" href="https://en.wikipedia.org/wiki/BRAF_(gene)" data-mce-href="https://en.wikipedia.org/wiki/BRAF_(gene)">BRAF</a>,<sup id="cite_ref-FDALabel_2-4" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2">[2]</a></sup> and as a second-line treatment for inoperable or metastatic melanoma following treatment of <a target="_blank" title="Ipilimumab" href="https://en.wikipedia.org/wiki/Ipilimumab" data-mce-href="https://en.wikipedia.org/wiki/Ipilimumab">ipilimumab</a> and, if the cancer has a BRAF mutation, a <a target="_blank" class="mw-redirect" title="BRAF inhibitor" href="https://en.wikipedia.org/wiki/BRAF_inhibitor" data-mce-href="https://en.wikipedia.org/wiki/BRAF_inhibitor">BRAF inhibitor</a>.<sup id="cite_ref-FDALabel_2-5" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2">[2]</a></sup><sup id="cite_ref-2015revMel_3-1" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-2015revMel-3" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-2015revMel-3">[3]</a></sup> It is also used to treat metastatic squamous <a target="_blank" class="mw-redirect" title="Non-small cell lung cancer" href="https://en.wikipedia.org/wiki/Non-small_cell_lung_cancer" data-mce-href="https://en.wikipedia.org/wiki/Non-small_cell_lung_cancer">non-small cell lung cancer</a> with progression with or after <a target="_blank" title="Platinum-based antineoplastic" href="https://en.wikipedia.org/wiki/Platinum-based_antineoplastic" data-mce-href="https://en.wikipedia.org/wiki/Platinum-based_antineoplastic">platinum-based drugs</a>.<sup id="cite_ref-FDALabel_2-6" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2">[2]</a></sup><sup id="cite_ref-2015revNSCLC_4-1" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-2015revNSCLC-4" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-2015revNSCLC-4">[4]</a></sup> It also used as a second-line treatment for <a target="_blank" title="Renal cell carcinoma" href="https://en.wikipedia.org/wiki/Renal_cell_carcinoma" data-mce-href="https://en.wikipedia.org/wiki/Renal_cell_carcinoma">renal cell carcinoma</a> after anti-angiogenic treatment has failed.<sup id="cite_ref-FDALabel_2-7" class="reference"><a target="_blank" href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2" data-mce-href="https://en.wikipedia.org/wiki/Nivolumab#cite_note-FDALabel-2">[2]</a></sup><b><sup id="cite_ref-FDALabel_2-7" class="reference"></sup></b></p>
  </li>`,
  `<li><a target="_blank" href="https://en.wikipedia.org/wiki/Cetuximab">cetuximab (Erbitux):&nbsp; metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer; BMS (US &amp; Canada),&nbsp;Merck KGaA (ROW except Japan), BMS, Merck KGaA, and&nbsp;Eli Lilly (Japan); 2009.﻿</a></li>`,
  `<li><a target="_blank" href="https://en.wikipedia.org/wiki/Ipilimumab"><span style="color: #222222; font-family: Arial;" data-mce-style="color: #222222; font-family: Arial;">﻿Ipilimumab</span> (trade name Yervoy) melanoma, BMS, 2011</a></li>`,

  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125554">OPDIVO(Nivolumab), Company: BRISTOL MYERS SQUIBB </a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514">KEYTRUDA, Company: MERCK SHARP DOHME</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034">TECENTRIQ, Company: GENENTECH INC</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761041">TECENTRIQ, Company: GENENTECH INC</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761049">BAVENCIO, Company: EMD SERONO INC</a></li>`,
  `<li><a target="_blank" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761078">BAVENCIO, Company: EMD SERONO INC</a></li>`,
];

const notFound = "<p style = 'color : #CB7BCB; font-size: 30px' >No Result</p>";

let activeItemId = "guidances";
let mainContent = $("#main-content");
mainContent.html(contents[activeItemId]);  

$(".list-group > a").click((e) => {
  let itemId = e.target.id;
  $(document.getElementById(activeItemId)).removeClass("active");
  activeItemId = itemId;
  $(document.getElementById(itemId)).addClass("active");
  mainContent.html(contents[itemId]);
});

$(".searchbar button").click((e) => {
  $(document.getElementById(activeItemId)).removeClass("active");
  activeItemId = undefined;
  let keyword = $(".searchbar input").val();
  $(".searchbar input").val("");
  let result = itemList.filter((item, idx) => {
    return item.toLowerCase().search(keyword.toLowerCase()) !== -1;
  });
  mainContent.html(`
    <h1 class="subtitle">Search Result</h1>
    <hr />
    <ul>
      ${result.length == 0 ? notFound : result.join("")}
    </ul>
  `);
});
